Biotech Prima Biomed shares are going nuts

Oli Scarff/Getty Images

Shares in tiny pharmaceutical Prima Biomed surged after a clinical trial showed its breast cancer drug is safe.

A short time ago, the shares were up 22.5% to $0.038.

“This very positive data is a major milestone,” says chief medical officer Dr Frédéric Triebel.

Prima BioMed is a globally active biotechnology company developing immunotherapeutic products.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at